Insights f s from
- m a
a For
- rmer FD
FDA Representat ative ve
Kris Evans, Executive Director, Quality Sciences Amgen, Inc.
Insights f s from om a a For ormer FD FDA Representat ative - - PowerPoint PPT Presentation
Insights f s from om a a For ormer FD FDA Representat ative ve Kris Evans, Executive Director, Quality Sciences Amgen, Inc. Introduction / Background US Food and Drug Administration Twenty (20) years as a Field Investigator and
Kris Evans, Executive Director, Quality Sciences Amgen, Inc.
the Guidance and Policy Team
manufacturing operations
including FDA Aseptic Processing Guidance
Technical Reports
their quality activities
Aseptic Behaviors Training
Subject Matter Experts
Oversight
Aseptic Council
Human Performance Tools
Metrics
Move Slowly and Deliberately Protect Sterility of Equipment, Components and Product Maintain Gowning Control Be Aware of Body Positioning Practice Good Hygiene
areas.
challenge beyond design and control parameters.
performing tasks, stand or sit still, with hands up and above waist level.
surfaces and Operators
differential pressure
surfaces
chamber is sterile
the most important training objective
closures, or unprotected critical surfaces with any part of their gown
barrier area and maintained in a manner to prevent contamination.
must take place away from the critical area and open product or containers.
areas that prevent skin exposure at all times within the aseptic core.
wall, equipment and other personnel.
touching a surface.
unidirectional air always flows first over sterile equipment surfaces, components, closures, and product without contacting non-sterile surfaces.
surfaces or components is needed, procedures must be followed including clearance, sanitization and sampling.
sunburns and flaking skin), and any infectious disease.
contamination.
classified area.